Business description
The Group managed by 4SC AG (ISIN DE000A14KL72) discovers and develops targeted, small-molecule drugs for treating diseases with high unmet medical needs in various cancer and autoimmune indications. These drugs are intended to provide innovative treatment options that are more tolerable and efficacious than existing therapies, and provide a better quality of life. The Company's pipeline comprises promising products that are in various stages of clinical development. 4SC's aim is to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies.
Management board & Supervisory board
| CEO |
| Dr. Jason Loveridge |
| Management board |
| Dr. med. Susanne Danhauser-Riedl, Kathleen Masch-Wiest |
| Supervisory board |
| Dr. Clemens Doppler, Dr. Irina Antonijevic, Dr. Manfred Rüdiger, Helmut Jeggle, Prof. Dr. Helga Rübsamen-Schaeff |
Company data
| Name: |
4SC AG |
| Address: |
Fraunhoferstraße 22,D-82152 Planegg-Martinsried |
| Phone: |
+49-89-700763-0 |
| Fax: |
- |
| E-mail: |
-
|
| Internet: |
www.4sc.de |
| Industry: |
Healthcare |
| Sector: |
Pharmaceutical Industry |
| Sub sector: |
Pharmaceuticals |
| End of financial year: |
12-31 |
| Free Float: |
- |
| IPO date: |
2005-12-15 |
Investor relations
| Name: |
- |
| IR phone: |
- |
| IR Fax: |
- |
| IR e-mail: |
ir-pr@4sc.com
|
